Insights into Tuberous Sclerosis Complex : From Genes to Clinics

Area of Science:

• Genetics
• Neurology
• Oncology

Background:

• Tuberous sclerosis complex (TSC) is an autosomal dominant genetic disorder.
• It stems from pathogenic variants in TSC1 or TSC2 genes.
• This leads to mammalian target of rapamycin (mTOR) pathway dysregulation.

Purpose of the Study:

• To highlight the diagnostic significance of clinical features in TSC.
• To emphasize the growing role of genetic testing in TSC diagnosis.
• To underscore the importance of long-term monitoring and multidisciplinary management for TSC.

Main Methods:

• Clinical feature analysis for diagnosis.
• Genetic testing for TSC1/TSC2 variants.
• Review of current and emerging therapeutic strategies.

Main Results:

• TSC is characterized by organ-specific tumors and neurological issues like seizures and developmental delays.
• Genetic testing is increasingly vital for accurate TSC diagnosis.
• mTOR pathway dysregulation is central to TSC pathogenesis.

Conclusions:

• Effective TSC management relies on early diagnosis through clinical and genetic evaluation.
• Multidisciplinary expert care is essential.
• Targeted therapies, including mTOR inhibitors, are key to improving clinical outcomes in TSC patients.